Novo Nordisk has filed a lawsuit against Eli Lilly over advertisements that compare the two companies' GLP-1 weight-loss medications, according to a report by MarketWatch. The Danish pharmaceutical giant claims that Lilly's ads do not include the most current clinical information about its drugs and that the comparisons are deliberately false.
The lawsuit puts two of the largest players in the rapidly growing GLP-1 drug market into direct legal conflict. GLP-1 medications, which were originally developed to treat type 2 diabetes, have become widely prescribed for weight loss and obesity management. The market has expanded sharply in recent years, with Novo Nordisk's semaglutide products and Lilly's tirzepatide-based drugs competing for patients and market share.
Novo Nordisk's complaint centers on the accuracy of Lilly's comparative advertising. The company argues that Lilly is drawing comparisons based on older clinical data rather than the most up-to-date information available, and that doing so misleads consumers and healthcare providers about the relative effectiveness of the two companies' treatments.
Eli Lilly has not yet publicly responded in detail to the lawsuit based on available reporting. The Financial Times also reported on the suit, describing Novo's characterization of the ads as "deliberately false."
The legal dispute comes at a critical moment for both companies. The GLP-1 category has attracted enormous investor attention and significant competition from compounding pharmacies that produce lower-cost alternatives. Both Novo Nordisk and Lilly have been working to defend their market positions as more patients gain access to these medications and as payers push back on high prices.
Novo Nordisk has faced its own share of pressures lately, including increased scrutiny of drug pricing and setbacks in clinical trials for some next-generation treatments. The lawsuit against Lilly represents an aggressive step in protecting what has become the company's most valuable franchise.
The case is expected to proceed in U.S. federal court. No trial date has been set based on currently available information.
